Cytotoxicity of the polyamine oxidase inactivator MDL 72527 to cancer cells: Comparison with a saturated structural analogue

International Journal of Oncology

Volumn 27, Issue 6, 2005, Pages 1669-1676

  Seiler, Nikolaus ^a   Renault, Jacques ^b   Gossé, Francine ^a   Roussi, Stamatiki ^a   Raul, Francis ^a  

^a IRCAD   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Cancer cells; Growth inhibition; L1210; MDL 72527; N1,N 4 di n butyl 1,4 butanediamine; Polyamine oxidase; SW620

Indexed keywords

DRUG DERIVATIVE; HYDROGEN PEROXIDE; N,N' BIS(2,3 BUTADIENYL)PUTRESCINE; OXIDOREDUCTASE; POLYAMINE; PUTRESCINE;

ANIMAL; ARTICLE; CELL PROLIFERATION; CELL STRAIN CACO 2; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ANIMALS; CACO-2 CELLS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROGEN PEROXIDE; MOLECULAR STRUCTURE; NEOPLASMS; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; POLYAMINES; PUTRESCINE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33644829741     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Seiler N, Duranton B and Raul F: The polyamine oxidase inactivator MDL 72527. Prog Drug Res 59: 1-40, 2002.
2. Bellelli A, Cavallo S, Nicolini L, Cervelli M, Bianchi M, Mariottini P, Zelli M and Federico R: Mouse spermine oxidase: a model of the catalytic cycle and its inhibition by N,N'-bis(2,3-butadienyl)-l,4-butanediamine. Biochem Biophys Res Commun 322: 1-8,2004.
3. Porter CW, McManis J, Casero RA and Bergeron RJ: Relative abilities of bis(ethyl)derivatives of putrescine, spermidine and spermine to regulate polyamine biosynthesis and inhibit L1210 leukemia cell growth. Cancer Res 47: 2821-2825,1987.
4. Seiler N: Thirty years of polyamine-related approaches in cancer therapy. Retrospect and prospect. Part 2. Structural analogues and derivatives. Current Drug Targets 4: 565-585, 2003.
5. Dai H, Kramer DL, Yanag C, Murti KG, Porter CW and Cleveland JL: The polyamine oxidase inhibitor MDL 72527 selectively induces apoptosis of transformed hematopoietic cells through lysosomotropic effects. Cancer Res 59: 4944-4954, 1999.
6. Duranton B, Holl V, Schneider Y, Carnesecchi S, Gosse F, Raul F and Seiler N: Cytotoxic effects of the polyamine oxidase inactivator MDL 72527 to two human colon carcinoma cell lines SW480 and SW620. Cell Biol Toxicol 18: 381-396, 2002.
7. Bey P, Bolkenius FN, Seiler N and Casara P: N-(2,3- butadienyl)-l,4- butanediamine derivatives: potent irreversible inactivators of mammalian polyamine oxidase. J Med Chem 28: 1-2,1985.
8. Li Y, Eiseman JL, Sentz DL, Rogers FA, Pan SS, Hu LT, Egorin MJ and Callery PS: Synthesis and antitumor evaluation of a highly potent cytotoxic DNA cross-linking polyamine analogue, l,12-diaziridinyl-4,9-diazadodecane. J Med Chem 39: 339-341,1996.
9. Leibowitz A, Stinson JC, McCombs WB III, McCoy CE, Mazur KC and Mabry ND: Classification of human colorectal adenocarcinoma cell lines. Cancer Res 36: 4562-4569,1976.
10. Mandel JL and Flintoff WF: Isolation of mutant mammalian cells altered in polyamine transport. J Cell Physiol 97: 335-344, 1978.
11. Persson L, Holm I, Ask A and Heby O: Curative effect of DL-2- difluoromethylornithine on mice bearing mutant L1210 leukemia cells deficient in polyamine uptake. Cancer Res 48: 4807-4811, 1988.
12. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MD: New colorimetric cytotoxicity assay for anti-cancer drug screening. J Natl Cancer Inst 82: 1107-1112,1990.
13. Crissman HA, Mullner PF and Steincamp JA: Methods and applications of flow systems for analysis and sorting of mammalian cells. Methods Cell Biol 9: 195-221,1975.
14. Nicoletti I, Mighorati G, Pagliacci MC, Grignani F and Riccardi C: A rapid and simple method for measuring thymocytes apoptosis by propidium iodide staining and flow cytometry. J Immunol Meth 139: 271-276,1991.
15. Bass DA, Parce W, Dechatelet LR, Szejda P, Seeds MC and Thomas M: Flow cytometry studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. J Immunol 130: 1910-1917,1983.
16. Seiler N, Sarhan S, Grauffel C, Jones R, Knödgen B and Moulinoux JP: Endogenous and exogenous polyamines in support of tumor growth. Cancer Res 50: 5077-5083,1990.
17. Seiler N, Bolkenius FN, Bey P, Mamont PS and Danzin C: Biochemical significance of inhibition of polyamine oxidase. In: Recent Progress in Polyamine Research. Selmeci L, Brosnan ME and Seiler N (eds). Akadémiai Kiado, Budapest, pp305-319, 1985.
18. Sarhan S, Knödgen B and Seiler N: Polyamine deprivation, malnutrition and tumor growth. Anticancer Res 12: 457-466, 1992.
19. Sarhan S, Quemener V, Moulinoux JP, Knödgen B and Seiler N: On the degradation and elimination of spermine by the vertebrate organism. Int J Biochem 23: 617-626, 1991.
20. Casero RA and Pegg AE: Spermidine/spermine N1-acetyltransferase - the turning point of polyamine metabolism. FASEB J 7:653-661,1993.
21. Badolo L, Hanocq M and Dubois J: Ability of bisbenzylputrescine-and propanediamine analogs to modulate the intracellular polyamine pool of P388D1 cells. Cell Biol Toxicol 14:419-428,1998.
22. Bolkenius FN and Seiler N: New substrates of polyamine oxidase. Dealkylation of N-alkyl-α,ω-diamines. Biol Chem Hoppe-Seyler 370: 525-531,1989.
23. Alzecang G, Harari P, Buldain G, Guerra L, Pickart M, Hernandez F and Frydman B: Antiproliferative effects of N1 ,N4-dibenzylputrescine in human and rodent tumor cells. Cell Mol Biol 44: 615-625,1998.
24. Huang Y, Pledgie A, Casero AR Jr and Davidson NE: Molecular mechanisms of polyamine analogs in cancer cells. Anticancer Drags 16: 229-341,2005.
25. Seiler N: Pharmacological aspects of cytotoxic polyamine analogs and derivatives for cancer therapy. Pharmacol Ther 107: 99-119,2005.
26. Bergeron RJ, McManis JS, Weimar WR, Schreier KM, Gao F, Wu Q, Ortiz-Ocasio J, Luchetta GR, Porter C and Vinson JR: The role of charge in polyamine analogue recognition. J Med Chem 38: 2278-2286,1995.
27. Quemener V, Moulinoux JP, Lucas J, Khan N, Darcel F, Martin LA, Primault R and Seiler N: The effects of structural analogs of putrescine on proliferation, morphology and karyotype of glioblastoma cells in culture. Biol Cell 77: 195-199, 1993.
28. Hochreiter R, Weiger TM, Colombatto S, Langer T, Thomas TJ, Cabella C, Heidegger W, Grillo MA and Hermann A: Long chain diamines inhibit growth of C6 glioma cells according to their hydrophobicity: an in vitro and molecular modelling study. Naunyn Schmiedebergs Arch Pharmacol 361: 235-246, 2000.
29. Tagliabue G, Pifferi A, Balconi G, Mascellani E, Geroni C, D'lncalci M and Ubezio P: Intracellular glutathione heterogeneity in L1210 murine leukaemia sublines made resistant to DNA-interacting anti-neoplastic agents. Int J Cancer 54: 435-442, 1993.
30. Chau YP, Shiah SG, Don MJ and Kuo ML: Involvement of hydrogen peroxide in topoisomerase inhibitor 8-lapachoneinduced apoptosis and differentiation of human leukaemia cells. Free Radical Bol Med 24: 660-670,1998.
31. Dröge W: Free radicals in the physiological control of cell function. Physiol Rev 82: 47-95, 2002.